Not a good buy right now for an impatient trader: trend is firmly bearish and probability model points to near-term downside (next week expectation -5.24%).
Price is sitting right on/just above key support (S1 ~1.378) with bearish momentum (MACD histogram negative and expanding), so breakdown risk is high.
No Intellectia buy signals (AI Stock Picker / SwingMax), no fresh news catalysts, and fundamentals still show ongoing losses with no revenue—this is not set up for an immediate upside move.
Momentum: MACD histogram -0.0104 and negatively expanding → selling pressure is increasing.
RSI(6): 23.558 → deeply oversold short-term, but oversold can stay oversold in a strong downtrend (not a reliable buy trigger by itself).
Levels: Pivot 1.502 (overhead), Resistance R1 1.626 / R2 1.703; Support S1 1.378 (very near current), S2 1.301. A clean reclaim of ~1.50 would be needed to argue for a quick long.
Positioning/Sentiment: Open interest put-call ratio 0.19 is call-heavy (bullish tilt), but this can also reflect speculative calls rather than informed conviction.
Activity/Liquidity: Very low absolute volume (total volume 5; puts 0) → options tape is thin and may be noisy.
Volatility: 30D IV ~220 vs historical vol ~86 → options are priced for large moves; however current IV is well below the recent 5D/10D averages, suggesting volatility has been coming down (less “event premium”).
Net take: Options skew looks bullish, but the data is too illiquid to outweigh the bearish chart setup.
Technical Summary
Sell
9
Buy
3
Positive Catalysts
~23.
can produce sharp bounces if support holds (around ~1.38).
Neutral/Negative Catalysts
No news in the recent week → no obvious near-term catalyst to reverse the downtrend.
Technical structure is bearish with weakening momentum (MACD negative expanding) and key support directly under price (S1 1.378); a break can quickly open room toward S2 (1.301).
Pattern-based forward view suggests downside bias over the next week (-5.24%).
No recent congress trading data available; no visible “influential buyer” tailwind from disclosed political transactions.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no operating revenue base; no growth signal).
Net income: -18.736M, slightly improved YoY (+0.53%), but still a meaningful loss.
Overall: Financials do not show an improving growth trajectory that would support an immediate re-rating without a clear catalyst.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so there is no confirmed recent Wall Street upgrade/downgrade trend to lean on.
Wall Street pros/cons view (based on provided data only): Pros—some institutional/hedge fund accumulation; Cons—ongoing losses with no revenue and a technically weak chart, making near-term timing unfavorable.
Wall Street analysts forecast JSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JSPR is 10.75 USD with a low forecast of 4 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast JSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JSPR is 10.75 USD with a low forecast of 4 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.270
Low
4
Averages
10.75
High
20
Current: 1.270
Low
4
Averages
10.75
High
20
Citizens JMP
Outperform
to
NULL
downgrade
$12 -> $6
AI Analysis
2025-09-22
Reason
Citizens JMP
Price Target
$12 -> $6
AI Analysis
2025-09-22
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Jasper Therapeutics to $6 from $12 and keeps an Outperform rating on the shares. Jasper Therapeutics announced early findings from its investigation into the confounding results from two cohorts in the BEACON study, and the issue now points to sites or enrolled patients, the analyst says. Jasper also announced the pricing of a $30M public offering, which will extend its runway past updated CSU data coming at year-end 2025 and into the third quarter of 2026. The bridge financing deal removes a key overhang for Jasper, Citizens says.
UBS
Buy
downgrade
$29 -> $25
2025-08-15
Reason
UBS
Price Target
$29 -> $25
2025-08-15
downgrade
Buy
Reason
UBS lowered the firm's price target on Jasper Therapeutics to $25 from $29 and keeps a Buy rating on the shares. Jasper's Q2 print was "straightforward," while the focus turns to the critical BEACON data in Q4, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JSPR
